Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors.
apheresis-donation
cellular therapy
donor health
hematopoietic stem cell
peripheral blood stem cell
stem cell
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
09
04
2021
received:
26
01
2021
accepted:
29
04
2021
pubmed:
24
6
2021
medline:
13
1
2022
entrez:
23
6
2021
Statut:
ppublish
Résumé
Increased transplant activity calls for improved stem cell collection, especially when peripheral blood is the preferred source of haematopoietic progenitor cells (HPCs). Plerixafor is a bicyclam molecule that mobilizes CD34+ cells by reversibly disrupting CXCR4-CXCL12-supported HPC retention. Plerixafor is given with granulocyte colony-stimulating factor (G-CSF) to help harvest autologous CD34+ cells for transplantation when mobilization with G-CSF fails. Mobilization protocols with the same doses of plerixafor and G-CSF have been used off-label in healthy allogeneic donors, with equal success and scarce side effects, both in adult and paediatric patients. Plerixafor has also been used as a sole mobilization agent. Plerixafor alone or coupled with G-CSF might lead to harvesting distinct cellular populations conferring improved engraftment properties and increased survival. Those characteristics might make plerixafor an especially attractive mobilization agent, particularly for non-related donations. However, available data are limited, and long-term follow-up is needed to clarify the best scenario for using plerixafor with or without G-CSF in healthy donors. In this review, we will summarize the evidence supporting this practice, highlighting the practical aspects and providing clues for an expanded use of plerixafor.
Substances chimiques
Benzylamines
0
Cyclams
0
Heterocyclic Compounds
0
Granulocyte Colony-Stimulating Factor
143011-72-7
plerixafor
S915P5499N
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6-16Informations de copyright
© 2021 International Society of Blood Transfusion.
Références
Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus. Bone Marrow Transplant. 2020;55:1604-13.
WMDA. WMDA Global Trends Report 2019. 2019. https://wmda.info/wp-content/uploads/2020/07/20201307-GTR-2019-Summary-slides.pdf. Accessed 24 Jan 2021.
Holtick U, Albrecht M, Chemnitz JM, Theurich S, Shimabukuro-Vornhagen A, Skoetz N, et al. Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015;94:179-88.
Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127:260-7.
Couban S, Wong PC, Schultz KR. The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation. Exp Hematol. 2019;70:1-9.
Spitzer TR, Kim SE, Cohen R, Mathews R, Li S, McAfee SL, et al. Declining bone marrow harvest quality over 24 years: a single institution experience. Bone Marrow Transplant. 2020;56:983-5.
Bredeson C, Leger C, Couban S, Simpson D, Huebsch L, Walker I, et al. An evaluation of the donor experience in the Canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant. 2004;10:405-14.
Couzin C, Manceau S, Diana JS, Joseph L, Magnani A, Magrin E, et al. Vascular access for optimal hematopoietic stem cell collection. J Clin Apher. 2020;36:12-9.
Dogu MH, Kaya AH, Berber I, Sari İ, Tekgündüz E, Erkurt MA, et al. Does the preference of peripheral versus central venous access in peripheral blood stem cell collection/yield change stem cell kinetics in autologous stem cell transplantation? Transfus Apher Sci. 2016;54:76-9.
Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. Cell Stem Cell. 2012;10:120-36.
Mohty M, Ho AD. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Exp Hematol. 2011;39:723-9.
Schmitz N, Dreger P. Peripheral blood hematopoietic cells for allogeneic transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, editors. Thomas' hematopoietic cell transplantation. Chichester, England: Wiley Blackwell; 2016. p. 460-8.
Giralt S, Costa L, Schriber J, DiPersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20:295-308.
DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:4767-73.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720-6.
Beelen DW, Ottinger H, Kolbe K, Pönisch W, Sayer HG, Knauf W, et al. Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study. Ann Hematol. 2002;81:701-9.
Teipel R, Schetelig J, Kramer M, Schmidt H, Schmidt AH, Thiede C, et al. Prediction of hematopoietic stem cell yield after mobilization with granulocyte-colony-stimulating factor in healthy unrelated donors. Transfusion. 2015;55:2855-63.
Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006;134:517-25.
Truong TH, Prokopishyn NL, Luu H, Guilcher GMT, Lewis VA. Predictive factors for successful peripheral blood stem cell mobilization and collection in children. J Clin Apher. 2019;34:598-606.
EMA. Plerixafor. ema.europa.eu, European Union, 2019. https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil. Accessed 7 Sept 2019.
FDA. Mozobil drug approval package. 2008. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000TOC.cfm. Accessed 24 Jan 2021.
Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112:990-8.
Hauge AW, Haastrup EK, Sengelov H, Minulescu L, Dickmeiss E, Fischer-Nielsen A. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion. 2014;54:1055-8.
Gattillo S, Marktel S, Rizzo L, Malato S, Malabarba L, Coppola M, et al. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation. Transfusion. 2015;55:1993-2000.
Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 2017;129:2680-92.
Teipel R, Oelschlägel U, Wetzko K, Schmiedgen M, Kramer M, Rücker-Braun E, et al. Differences in cellular Composition of peripheral blood stem cell grafts from healthy stem cell donors mobilized with either granulocyte colony-stimulating factor (G-CSF) alone or G-CSF and Plerixafor. Biol Blood Marrow Transplant. 2018;24:2171-7.
de Greef GE, Braakman E, van der Holt B, Janssen JJWM, Petersen E, Vucinic V, et al. The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 study. Transfusion. 2019;59:316-24.
Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, et al. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv. 2019;3:875-83.
Zubicaray J, Galvez E, Sebastian E, Molina B, González-Vicent M, Castillo A, et al. Plerixafor-based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better CD34(+) collection yield: a retrospective analysis. J Clin Apher. 2020;36:78-86.
Holig K, Schmidt H, Hutter G, Kramer M, Teipel R, Heidrich K, et al. Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial. Bone Marrow Transplant. 2020;56:635-45.
Kharya G, Bakane A, Agarwal S, Rauthan A. Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease. Bone Marrow Transplant. 2020;56:492-504.
Cid J, Monsalvo S, Castillo C, Pascual C, Moreno-Jiménez G, López-Parra M, et al. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: an observational case series on behalf of the Grupo Espanol de Trasplante Hematopoyetico (GETH). Transfus Apher Sci. 2021;60:103052.
Hoggatt J, Singh P, Tate TA, Chou B-K, Datari SR, Fukuda S, et al. Rapid mobilization reveals a highly engraftable hematopoietic stem cell. Cell. 2018;172:191-204.e10.
Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000;44:1667-73.
Wang J, Tannous BA, Poznansky MC, Chen H. CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent. Pharmacol Res. 2020;159:105010.
Pelus LM, Broxmeyer HE. Peripheral blood stem cell mobilization; a look ahead. Curr Stem Cell Rep. 2018;4:273-81.
Guyon A. CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci. 2014;8:65.
Nagasawa T. CXCL12/SDF-1 and CXCR4. Front Immunol. 2015;6:301.
De Clercq E. AMD3100/CXCR4 inhibitor. Front Immunol. 2015;6:276.
Liles WC, Broxmeyer HE, Rodger E, Wood B, Hübel K, Cooper S, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102:2728-30.
Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005;45:295-300.
Allen ES, Conry-Cantilena C. Mobilization and collection of cells in the hematologic compartment for cellular therapies: stem cell collection with G-CSF/plerixafor, collecting lymphocytes/monocytes. Semin Hematol. 2019;56:248-56.
Douglas KW, Gilleece M, Hayden P, Hunter H, Johnson PRE, Kallmeyer C, et al. UKconsensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. J Clin Apher. 2018;33:46-59.
Kriegsmann K, Wuchter P. Mobilization and collection of peripheral blood stem cells in adults: focus on timing and benchmarking. Methods Mol Biol. 2017;2019:41-58.
Hübel K. Mobilization and collection of HSC. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook hematopoietic stem cell transplantation and cellular therapies. Cham, Switzerland: Springer Nature Switzerland AG; 2019. p. 117-22.
Kimura S, Ohkawara H, Minakawa K, Fukatsu M, Mori H, Takahashi H, et al. Optimal timing of apheresis for the efficient mobilization of peripheral blood progenitor cells recruited by high-dose granulocyte colony-stimulating factor in healthy donors. Transfus Apher Sci. 2020;59:102737.
Kong JH, Hu Y, Shim H, Lee E, Lee H, Eom HS, et al. Analysis of factors associated with successful allogeneic peripheral blood stem cell collection in healthy donors. Transfus Apher Sci. 2020;59:102679.
Benakli M, Ahmed Nacer R, Mehdid F, Belhadj R, Rahmoune N, Baazizi M, et al. Peripheral blood stem cell mobilization and collection in pediatric healthy sibling donors weighing 20 kilograms or less; algerian experience. Transfus Apher Sci. 2020;59:102987.
Suzuya H, Watanabe T, Nakagawa R, Watanabe H, Okamoto Y, Onishi T, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang. 2005;89:229-35.
Leotta S, Poidomani M, Mauro E, Spadaro A, Marturano E, Milone G. AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest. Bone Marrow Transplant. 2011;46:314-6.
Schriber J, Fauble V, Sproat LO, Briggs A. Plerixafor ‘just in time’ for stem cell mobilization in a normal donor. Bone Marrow Transplant. 2011;46:1026-7.
Eyre TA, King AJ, Peniket A, Rocha V, Collins GP, Pawson R. Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest. Transfusion. 2014;54:1231-4.
Neumann T, Kruger WH, Busemann C, Kiefer T, Dolken G. Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone. Bone Marrow Transplant. 2011;46:762-3.
Pantin J, Purev E, Tian X, Cook L, Donohue-Jerussi T, Cho E, et al. Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102:600-9.
Goren Sahin D, Arat M. Peripheral blood stem cell collection for allogeneic hematopoietic stem cell transplantation: practical implications after 200 consequent transplants. Transfus Apher Sci. 2017;56:800-3.
Hauser RG, Kwon RJ, Ryder A, Cheng C, Charifa A, Tormey C. Transfusion medicine equations made internet accessible. Transfus Med Rev. 2020;34:5-9.
Bartnik K, Maciejewska M, Farhan R, Urbanowska E, Król M, Król M, et al. Continuous mononuclear cell collection (cMNC) protocol impact on hematopoietic stem cell collections in donors with negative collection predictors. Transfus Apher Sci. 2018;57:401-5.
Cid J, Castillo C, Marin P, Carbassé G, Herrera D, Monfort N, et al. Increased collection efficiency of CD34+ cells after mobilization with preemptive use of plerixafor followed by leukocytapheresis on the same day. Transfusion. 2020;60:779-85.
Gromme M, Russcher H, Braakman E, Klinkspoor JH, Dobber JA, de Greef I, et al. Multicenter study to evaluate a new enumeration method for hematopoietic stem cell collection management. Transfusion. 2017;57:1949-55.
Valtola J, Silvennoinen R, Ropponen A, Siitonen T, Säily M, Sankelo M, et al. Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study. Leuk Lymphoma. 2019;60:453-61.
Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH, et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia. 2003;17:869-75.
Mielcarek M, Martin PJ, Heimfeld S, Storb R, Torok-Storb B. CD34 cell dose and chronic graft-versus-host disease after human leukocyte antigen-matched sibling hematopoietic stem cell transplantation. Leuk Lymphoma. 2004;45:27-34.
Urbano-Ispizua A, Carreras E, Marin P, Rovira M, Martı́nez C, Fernández-Avilés F, et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells? Blood. 2001;98:2352-7.
Karres D, Ali S, van Hennik PB, Straus S, Josephson F, Thole G, et al. EMA recommendation for the pediatric indications of plerixafor (Mozobil) to enhance mobilization of hematopoietic stem cells for collection and subsequent autologous transplantation in children with lymphoma or malignant solid tumors. Oncologist. 2020;25:e976-e81.
Uchida N, Leonard A, Stroncek D, Panch SR, West K, Molloy E, et al. Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor. Haematologica. 2020;105:e497.
Worel N, Frank N, Frech C, Fritsch G. Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes. Transfusion. 2017;57:2206-15.
Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi S, et al. Improved survival after transplantation of more donor plasmacytoid dendritic or naive T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. J Clin Oncol. 2014;32:2365-72.
Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:339-48.
Benguerfi S, Thepault F, Lena H, Ricordel C. Spontaneous splenic rupture as a rare complication of G-CSF injection. BMJ Case Rep. 2018;2018.
Azar N, Ouzegdouh M, Choquet S, Leblond V. Impact of plerixafor (mozobil) on hospital efficiency: a single center experience. J Clin Apher. 2018;33:5-13.
Verlinden A, Van de Velde A, Verpooten GA, van Doorn KJ. Determining factors predictive of CD34+ cell collection efficiency in an effort to avoid extended and repeated apheresis sessions. J Clin Apher. 2013;28:404-10.
Watts NL, Marques MB, Peavey DB, Innis-Shelton R, Saad A, AD S, et al. Mobilization of hematopoietic progenitor cells for autologous transplantation using Pegfilgrastim and Plerixafor: efficacy and cost implications. Biol Blood Marrow Transplant. 2019;25:233-8.
Andritsos LA, Huang Y, Abraham I, Huff K, Scrape SR, Fan T, et al. Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. Leuk Res. 2019;85:106215.
McDermott DH, Pastrana DV, Calvo KR, Pittaluga S, Velez D, Cho E, et al. Plerixafor for the treatment of WHIM syndrome. N Engl J Med. 2019;380:163-70.